Ravicti access in Pakistan
How families in Pakistan access Ravicti (glycerol phenylbutyrate) for chronic management of urea cycle disorders through the DRAP Special Permission Personal Use Import pathway.
Ask about Ravicti in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
1. Quick orientation
Ravicti is an oral liquid prescribed for the chronic, lifelong management of urea cycle disorders (UCDs) in pediatric and adult patients who cannot be managed on protein restriction alone. It is FDA-approved and manufactured by Horizon Therapeutics USA, Inc., now a subsidiary of Amgen. In Pakistan, Ravicti is not registered with the Drug Regulatory Authority of Pakistan (DRAP), and families with a confirmed UCD diagnosis routinely reach for the medicine through the DRAP Special Permission framework, also referred to as the No Objection Certificate for Personal Use Import. Reserve Meds coordinates the United States sourcing, the regulatory documentation kit, and the international logistics into a Karachi, Lahore, or Islamabad dispensing facility, while clinical decisions remain with your treating metabolic geneticist or pediatric specialist.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
2. Why Pakistan families need Ravicti through the named-patient pathway
Urea cycle disorders are ultra-rare, with a combined incidence below one in 35,000 live births. Local commercial registration of UCD therapies is uneconomic in Pakistan's small specialty market, and Ravicti is therefore not on the DRAP register. Sodium phenylbutyrate (Buphenyl), the principal pharmacologic alternative for chronic UCD management, is also rarely held in Pakistani hospital pharmacies. Carglumic acid is indicated for the NAGS-deficiency UCD subtype specifically and is not a general substitute. Pakistan's specialty pharmaceutical market is cash-pay dominant for advanced therapies, and even families with private insurance through private insurers rarely find named-patient imports covered.
The chronicity of the need is what makes the gap unusually painful for UCD families. A child diagnosed in the neonatal period or early infancy needs Ravicti continuously, year after year, for life. Without a documented import route, families end up making ad hoc decisions every refill cycle. The DRAP Special Permission pathway converts that into a repeatable workflow.
3. The DRAP Special Permission pathway for Ravicti
DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing Division's Import and Export Section, with Drug Registration Board oversight on new product matters. For unregistered medicines required by a specific patient, DRAP issues a Special Permission, also called the No Objection Certificate (NOC) for Personal Use Import. Applications are filed through DRAP's Online Import and Export System (OIES). For Ravicti, the pathway is the Personal Use Import sub-permission for the patient, or the institutional Special Permission for Import of Unregistered Therapeutic Goods where the hospital pharmacy files on the family's behalf.
The application package for a Ravicti case typically includes the treating physician's clinical justification letter setting out the confirmed UCD diagnosis (the specific enzyme defect, such as OTC deficiency, CPS1 deficiency, ASS1, ASL, or NAGS deficiency), the molecular genetic confirmation report, the patient's current weight, the current plasma ammonia and metabolite panel, prior phenylbutyrate experience if any, and the dosing plan against the FDA label. The PMDC license verification of the treating physician is attached. The patient identifier is the B-Form for minors (the typical Ravicti case) or the CNIC for adult UCD patients. Product details include the brand name (Ravicti), the generic name (glycerol phenylbutyrate), the manufacturer (Horizon Therapeutics USA, Inc., subsidiary of Amgen), strength (25 mL multi-dose oral liquid bottles), and the projected three to six month supply quantity to support refill planning. A manufacturer or authorized distributor letter confirms the product is genuine and sourced through the legitimate United States DSCSA-compliant chain. The dispensing facility's institutional license accompanies the package.
We give you a written timeline estimate for your case before you commit. Complex pediatric cases, particularly neonatal-onset UCD presentations, are usually framed clearly enough by the treating metabolic geneticist that the DRAP review is straightforward. The cell-specific clinical-justification angle for Ravicti is the documented molecular-genetic UCD diagnosis paired with the lifelong-chronicity framing, which positions the case clearly within the Personal Use Import scope rather than a one-off clinical trial supply request.
4. Where Ravicti gets dispensed in Pakistan
Ravicti dispensing in Pakistan concentrates at the tertiary pediatric and metabolic genetics centers with the import pharmacy infrastructure to receive an unregistered oral liquid.
Because Ravicti is room-temperature stable, the dispensing facility does not need refrigerated storage for the product itself, which materially widens the institutional list relative to a cold-chain biologic. The constraint is institutional licensing and the DRAP relationship, not the cold-chain infrastructure.
5. Real cost picture for Ravicti in Pakistan
Medicine price: quote on request. You get a written quote for your case before you commit.
6. Typical timeline for Ravicti in Pakistan
We give you a written timeline estimate for your case before you commit. Reserve Meds plans on the longer end of this range and treats faster turnaround as upside. Because Ravicti is room-temperature stable, the physical logistics leg does not extend the timeline the way a cold-chain biologic does; standard insulated packaging without active cooling is sufficient and adds two to four days for international air freight plus Federal Board of Revenue (FBR) Customs clearance at Karachi seaport or Karachi, Lahore, or Islamabad airports. Refill cadence is set per patient based on dispensed pack quantity and projected daily volume; the multi-dose 25 mL glass bottle format produces large pack quantities for adolescent and adult doses, so refill scheduling typically runs every three to four months rather than monthly.
7. What your physician needs to provide
The clinical justification letter, signed by a PMDC-licensed physician, is the cornerstone of the application. For Ravicti, the letter sets out the confirmed UCD diagnosis with the specific enzyme deficiency identified by molecular genetic testing, the failure or inadequacy of dietary protein restriction alone, the patient's current weight (and body surface area where calculated), the current plasma ammonia value with reference range, the plasma glutamine and branched-chain amino acid context, and the dosing plan referenced to the FDA package insert. For phenylbutyrate-naive patients, the FDA label provides a starting estimate of 4.5 to 11.2 mL per square metre of body surface area per day, divided three times daily with meals or feeds, with a maximum total daily dose of 17.5 mL. An alternative protein-based starting estimate is 0.6 mL per gram of dietary protein per 24 hours. For patients transitioning from sodium phenylbutyrate to Ravicti, the label provides a milligram-to-milligram conversion.
The monitoring plan attached to the application typically describes plasma ammonia targets (in patients aged 6 years and older, the label directs titration to maintain fasting plasma ammonia below half the upper limit of normal; in younger children, the morning ammonia is targeted to below the age-appropriate upper limit), the PAA to PAGN ratio as a decision aid where elevated, and routine liver function tests. Growth velocity, weight, and nutritional adequacy are followed in pediatric patients alongside the metabolic panel. Adverse events, if any, are reported by the treating physician through the DRAP Pharmacovigilance Centre as the post-import obligation.
8. Common questions about Ravicti in Pakistan
Will a private insurer cover Ravicti? Coverage for named-patient imports of unregistered specialty drugs is uncommon across Pakistani health plans. Some private health plans cover in-hospital chemotherapy and radiotherapy in their formularies, but ultra-rare metabolic specialty imports are typically outside formulary. Reserve Meds supplies the documentation an insurer needs to assess the claim, but the claim itself is yours or your hospital's to file. The realistic default is cash-pay.
Does Sehat Sahulat help? Medicine price: quote on request. Every case gets a written custom quote before you commit. Sehat Sahulat can still cover hospitalization, supportive care, and procedures while the Ravicti supply is procured separately on a cash-pay basis.
Can my child receive Ravicti at home rather than at a hospital? The dispensing facility must hold a Pakistani license. For an oral liquid like Ravicti, a hospital outpatient pharmacy or specialized licensed import pharmacy dispenses the product. Once dispensed, administration at home with meals or feeds is the normal pattern, since Ravicti is an outpatient chronic-management medicine.
What is the safety profile? The FDA label lists the most common adverse reactions in adult clinical studies as diarrhoea, flatulence, and headache, and in pediatric patients as upper respiratory tract infection, vomiting, diarrhoea, decreased appetite, fatigue, and rash. Neurotoxicity of phenylacetate is the principal warning, with monitoring for symptoms such as somnolence, confusion, and lethargy when plasma phenylacetic acid (PAA) is elevated.
Why Ravicti rather than sodium phenylbutyrate? The metabolic genetics literature reports better palatability and lower sodium intake with Ravicti, which can be material in young children and in patients with cardiac or fluid considerations. The clinical choice belongs to the treating physician. Reserve Meds does not endorse one product over the other.
How does diaspora-pooled funding work for Ravicti refills? Pakistan's diaspora pattern is well-established, with major remittance corridors from Saudi Arabia, the UAE, the United Kingdom, the United States, and Canada. Many UCD families fund annual Ravicti supply by pooling resources across overseas relatives.
9. Where Reserve Meds fits in Ravicti cases
Reserve Meds is a US-based digital health company. We do not replace your treating metabolic geneticist, we do not replace DRAP, we do not replace your dispensing hospital pharmacy or the in-country importer. What we do for a Ravicti case is orchestrate the United States-side sourcing from the limited specialty pharmacy network that holds Horizon's Ravicti supply, the regulatory documentation kit for the DRAP Personal Use Import application, the international logistics for room-temperature oral liquid through bonded air freight, the FBR Customs coordination at the port of entry, and a single point of contact who stays with your family across refill cycles. Because UCD therapy is lifelong, Reserve Meds plans the relationship as a multi-year coordination rather than a one-time procurement.
Standard NPP coordination applies.
10. Next step
We confirm eligibility within one business day and send the documentation kit to your physician and hospital pharmacy.